-
Sep 2023
Shifts in isoform usage underlie transcriptional differences in regulatory T cells in type 1 diabetes.
Commun BiolNewman JRB, Long SA, Speake C, Greenbaum CJ, Cerosaletti K, Rich SS, Onengut-Gumuscu S, McIntyre LM, Buckner JH, Concannon P -
Sep 2023
High proinsulin:C-peptide ratio identifies individuals with stage 2 type 1 diabetes at high risk for progression to clinical diagnosis and responses to teplizumab treatment.
DiabetologiaSims EK, Geyer SM, Long SA, Herold KC -
Mar 2023
Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial.
Diabetes CareRussell WE, Bundy BN, Anderson MS, Cooney LA, Gitelman SE, Goland RS, Gottlieb PA, Greenbaum CJ, Haller MJ, Krischer JP, Libman IM, Linsley PS, Long SA, Lord SM, Moore DJ, Moore WV, Moran AM, Muir AB, Raskin P, Skyler JS, Wentworth JM, Wherrett DK, Wilson DM, Ziegler AG, Herold KC, Type 1 Diabetes TrialNet Study Group -
Nov 2022
Inflammatory bone marrow signaling in pediatric acute myeloid leukemia distinguishes patients with poor outcomes.
Nat CommunBolouri H, Ries RE, Wiedeman AE, Hylkema T, Scheiding S, Gersuk VH, O'Brien K, Nguyen QA, Smith JL, Long SA, Meshinchi S -
Aug 2022
Clinical and Experimental Treatment of Type-1 Diabetes.
Clin Exp ImmunolLong SA, Buckner JH -
May 2022
Chemokines, Soluble PD-L1, and Immune Cell Hyporesponsiveness are Distinct Features of SARS-CoV-2 Critical Illness.
Am J Physiol Lung Cell Mol PhysiolMorrell ED, Bhatraju PK, Sathe NA, Lawson J, Mabrey L, Holton SE, Presnell SR, Wiedeman A, Acosta-Vega C, Mitchem MA, Liu T, Chai XY, Sahi S, Brager C, Orlov M, Sakr SS, Sader A, Lum DM, Koetje N, Garay A, Barnes E, Cromer G, Bray MK, Pipavath S, Fink SL, Evans L, Long SA, West TE, Wurfel MM, Mikacenic C -
Apr 2022
A simple strategy for sample annotation error detection in cytometry datasets.
Cytometry ASmithmyer ME, Wiedeman AE, Skibinski DAG, Savage AK, Acosta-Vega C, Scheiding S, Gersuk VH, O'Rourke C, Long SA, Buckner JH, Speake C -
Mar 2022
Single Nucleotide Variant in FAS Associates With Organ Failure and Soluble Fas Cell Surface Death Receptor in Critical Illness.
Crit Care MedMikacenic C, Bhatraju P, Robinson-Cohen C, Kosamo S, Fohner AE, Dmyterko V, Long SA, Cerosaletti K, Calfee CS, Matthay MA, Walley KR, Russell JA, Christie JD, Meyer NJ, Christiani DC, Wurfel MM -
Jan 2022
Guidelines for standardizing T-cell cytometry assays to link biomarkers, mechanisms, and disease outcomes in type 1 diabetes.
Eur J ImmunolYang JHM, Ward-Hartstonge KA, Perry DJ, Blanchfield JL, Posgai AL, Wiedeman AE, Diggins K, Rahman A, Tree TIM, Brusko TM, Levings MK, James EA, Kent SC, Speake C, Homann D, Long SA, Immunology of Diabetes Society T-Cell Cytometry Group. -
Jan 2022
Deep immune phenotyping reveals similarities between aging, Down syndrome, and autoimmunity.
Sci Transl MedLambert K, Moo KG, Arnett A, Goel G, Hu A, Flynn KJ, Speake C, Wiedeman AE, Gersuk VH, Linsley PS, Greenbaum CJ, Long SA, Partridge R, Buckner JH, Khor B -
Nov 2021
A phase 1b open-label dose-finding study of ustekinumab in young adults with type 1 diabetes.
Immunother AdvMarwaha AK, Chow S, Pesenacker AM, Cook L, Sun A, Long SA, Yang JHM, Ward-Hartstonge KA, Williams E, Domingo-Vila C, Halani K, Harris KM, Tree TIM, Levings MK, Elliott T, Tan R, Dutz JP -
Nov 2021
IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetes.
JCI InsightGreenbaum CJ, Serti E, Lambert K, Weiner LJ, Kanaparthi S, Lord S, Gitelman SE, Wilson DM, Gaglia JL, Griffin KJ, Russell WE, Raskin P, Moran A, Willi SM, Tsalikian E, DiMeglio LA, Herold KC, Moore WV, Goland R, Harris M, Craig ME, Schatz DA, Baidal DA, Rodriguez H, Utzschneider KM, Nel HJ, Soppe CL, Boyle KD, Cerosaletti K, Keyes-Elstein L, Long SA, Thomas R, McNamara JG, Buckner JH, Sanda S, ITN058AI EXTEND Study Team. -
Aug 2021
Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet Diabetes EndocrinolGitelman SE, Bundy BN, Ferrannini E, Lim N, Blanchfield JL, DiMeglio LA, Felner EI, Gaglia JL, Gottlieb PA, Long SA, Mari A, Mirmira RG, Raskin P, Sanda S, Tsalikian E, Wentworth JM, Willi SM, Krischer JP, Bluestone JA, Gleevec Trial Study Group. -
May 2021
The many faces of islet antigen-specific CD8 T cells: clues to clinical outcome in type 1 diabetes.
Immunol Cell BiolWiedeman AE, Speake C, Long SA -
Apr 2021
Combination therapy in recent-onset type 1 diabetes.
Lancet Diabetes EndocrinolLong SA, Speake C
